The pathophysiology of peripheral arterial disease: Rational targets for drug intervention

Vascular Medicine

Volumn 2, Issue 3, 1997, Pages 227-230

  Cooke, John P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Peripheral arterial disease

Indexed keywords

ANGIOGENIC FACTOR; ANTIOXIDANT; ARGININE DERIVATIVE; ATORVASTATIN; FIBROBLAST GROWTH FACTOR; HOMOCYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPROTEIN A; MATRIX METALLOPROTEINASE INHIBITOR; NITRIC OXIDE; NITRIC OXIDE DONOR; PROPIONYLCARNITINE; PROSTANOID; RANOLAZINE; VASCULOTROPIN; VASODILATOR AGENT;

ARTERY DISEASE; ATHEROSCLEROSIS; CONFERENCE PAPER; HOMOCYSTINURIA; HUMAN; LIMB ISCHEMIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030777782     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X9700200311     Document Type: Conference Paper

References (26)

1. Ross R The pathogenesis of atherosclerosis. N Engl J Med 1986; 314: 488-500.
2. McLenachan JM, Vita J, Fish RD et al. Early evidence of endothelial vasodilator dysfunction at coronary branch points. Circulation 1990, 82: 1169-73.
3. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788-91
4. Libby P. Molecular bases of the acute coronary syndrome. Circulation 1995; 91: 2844-50.
5. European Working Group on Critical Leg Ischemia. Second European consensus document on chronic critical leg ischemia Circulation 1991; 84 (suppl IV): IV-1-IV-26.
6. Harrison DG, Armstrong ML, Freiman P, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80: 1808-11.
7. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993, 87: 1781-91.
8. Candipan RC, Wang BY, Tsao PS, Cooke JP Regression or progression: dependency upon vascular nitric oxide activity. Arterioscler Thromb Vasc Biol 1996; 16: 44-50.
9. Böger RH, Bode-Böger SM, Frölich JC. The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis 1996; 127: 1-11.
10. Tsao PS, Buitrago R, Chang H, Chen YDI, Reaven G. Effect of diabetes on monocyte-endothelial interactions and endothelial superoxide production in fructose-induced insulin-resistant and hypertensive rats. Circulation 1995, 92 (suppl I). I-558.
11. Weber C, Erl W, Pietsch A et al. Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kb mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Arterioscler Thromb 1994, 14: 1665-73.
12. Marui N, Offerman MK, Swerlick R et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92: 1866-74.
13. Zeiher Am, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995; 76: 980-86.
14. Tsao PS, Buitrago R, Chan JR, Cooke JP. Fluid flow inhibits endothelial adhesiveness: NO and transcriptional regulation of VCAM-1 Circulation 1996; 94: 1682-89.
15. Tsao PS, Wang BY, Buitrago R, Shyy JYJ, Cooke JP. Nitric oxide regulates monocyte chemotactic protein 0-1. Circulation 1997 (in press).
16. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-27.
17. Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherogenesis and thrombosis. Annu Rev Med 1996; 47: 423-42.
18. Maher VM, Brown BG. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol 1995; 6: 229-35.
19. Liu AC, Lawn RM. Vascular interactions of lipoprotein(a). Curr Opin Lipidol 1994; 5: 269-73.
20. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339 572-75.
21. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham MC. Anti-atherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90: 1168-72.
22. Cayette AJ, Palacine JJ, Horten K, Cohen RA Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits Arterioscler Thromb 1994, 14: 746-52.
23. Bode-Böger SM, Boger RH, Kienke S, Junker W, Frolich JC Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598-603.
24. Bode-Böger SM, Boger RH, Alfke H et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation 1996; 93 85-90
25. Yang HT, Deschenes MR, Ogilvie RW, Terjung RL. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ Res 1996; 79: 62-69.
26. Takeshita S, Zheng L, Isner J. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb mode. J Clin Invest 1994, 93: 662-70.